LOGIN  |  REGISTER

Avinger (NASDAQ: AVGR) Stock Quote

Follow Insider Trades Visit website
Last Trade: US$11.18 -2.61 -18.93
Volume: 7,161,834
5-Day Change: 141.47%
YTD Change: 925.69%
Market Cap: US$8.020M

Latest News From Avinger

September 18, 2023
Avinger Initiates Full Commercial Launch of Tigereye ST Image-Guided CTO Crossing Device
REDWOOD CITY, CA / ACCESSWIRE / September 18, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced full commercial launch of its Tigereye® ST next generation image-guided chronic total occlusion (CTO) crossing system. With the initiation of full commercial... Read More
August 24, 2023
Avinger Announces Presentations by Key Opinion Leaders at AMP (The Amputation Prevention Symposium) 2023
REDWOOD CITY, CA / ACCESSWIRE / August 24, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced three podium presentations featuring the company's Lumivascular technology at The Amputation Prevention Symposium, held from August 16 through August 19 in... Read More
August 4, 2023
Avinger Announces Conversion of 12% of CRG Term Debt into Equity
REDWOOD CITY, CA / ACCESSWIRE / August 4, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today announced the conversion of approximately 12% of its existing debt with entities affiliated with CRG Partners III L.P. ("CRG") into shares of a new series of... Read More
July 20, 2023
Avinger to Announce Second Quarter 2023 Results on July 27
REDWOOD CITY, CA / ACCESSWIRE / July 20, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the second quarter 2023 after the close of trading on Thursday, July 27, 2023. The Company will host a conference call... Read More
June 20, 2023
Avinger Announces Presentations by Key Opinion Leaders at LINC 2023
REDWOOD CITY, CA / ACCESSWIRE / June 20, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced two podium presentations featuring the company's Lumivascular technology at the Leipzig Interventional Course (LINC) 2023, which took place June 6 through June 9.... Read More
June 9, 2023
Avinger Announces Presentations by Key Opinion Leaders at New Cardiovascular Horizons Annual Conference
REDWOOD CITY, CA / ACCESSWIRE / June 9, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced two podium presentations featuring the company's Lumivascular technology at the New Cardiovascular Horizons (NCVH) annual conference, which took place May 30 through... Read More
June 7, 2023
Avinger Receives 510(k) Clearance for Pantheris LV Image-Guided Atherectomy System
REDWOOD CITY, CA / ACCESSWIRE / June 7, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the company has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for Pantheris® LV, its next-generation image-guided atherectomy system for... Read More
June 5, 2023
Avinger Announces Successful First Cases with Tigereye ST Image-Guided Chronic Total Occlusion (CTO) Crossing Device
REDWOOD CITY, CA / ACCESSWIRE / June 5, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the successful completion of the first clinical cases with the new Tigereye ST image-guided CTO crossing system. Dr. Ian Cawich, an interventional cardiologist at... Read More
May 10, 2023
Avinger Reports First Quarter 2023 Results
REDWOOD CITY, CA / ACCESSWIRE / May 10, 2023 / Avinger, Inc . (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the first quarter ended March 31, 2023. First Quarter and Recent Highlights First quarter revenue of $1.9 million, and gross margin of 34%... Read More
May 2, 2023
Avinger to Announce First Quarter 2023 Results on May 10
REDWOOD CITY, CA / ACCESSWIRE / May 2, 2023 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the first quarter 2023 after the close of trading on Wednesday, May 10, 2023. The Company will host a conference call... Read More
April 28, 2023
Leading Data on the Treatment of In-Stent Restenosis with Pantheris Presented at Charing Cross International Symposium
REDWOOD CITY, CA / ACCESSWIRE / April 28, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the presentation of clinical data from the INSIGHT study during the Charing Cross (CX) International Symposium in London, England. The CX Symposium... Read More
April 26, 2023
Avinger Receives 510(k) Clearance for Tigereye ST Image-Guided CTO Crossing System
REDWOOD CITY, CA / ACCESSWIRE / April 26, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced the company has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for Tigereye ® ST, its next-generation image-guided chronic total occlusion... Read More
March 15, 2023
Avinger Reports Fourth Quarter 2022 Results
REDWOOD CITY, CA / ACCESSWIRE / March 15, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease, today reported results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter and Recent Highlights Fourth quarter revenue of $2.0 million,... Read More
March 2, 2023
Avinger to Announce Fourth Quarter 2022 Results on March 15
REDWOOD CITY, CA / ACCESSWIRE / March 2, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of vascular disease, today announced that it will release its financial results for the fourth quarter and full year 2022 after the close of trading on Wednesday, March 15, 2023. The Company will host a... Read More
January 11, 2023
Avinger Announces 510(k) Filing of Pantheris LV
Pantheris LV Represents the Next-Generation of Onboard Image-Guided Technology for the Treatment of Peripheral Artery Disease REDWOOD CITY, CA / ACCESSWIRE / January 11, 2023 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the Company submitted... Read More
C4 Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB

  Research Tools
  News & Announcements
  Popular Topics
  Miscellaneous